A phase II, randomized, double-blind, placebo-controlled study comparing the combination of CNTO 328 (anti-IL-6 monoclonal antibody) and Velcade versus Velcade alone in subjects with relapsed or refractory multiple myeloma
Laufzeit: 01.01.2008 - 31.12.2011